IRVINE, Calif., June 18 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products for cardiac revascularization today announced an upcoming scientific presentation that describes the use of combining transmyocardial revascularization (TMR) with platelet rich plasma (PRP).
The presentation titled "Intramyocardial Injection of Autologous Platelet Rich Plasma combined with Transmyocardial Revascularization" will be presented by Kurt E. Wehberg, MD of Peninsula Regional Medical Center (Salisbury, Maryland) at the 34th annual meeting of the Western Thoracic Surgical Association on June 28, 2008 in Kona, Hawaii. The abstract of the presentation is available at http://www.westernthoracic.org/Abstracts/2008/BC8.html.
Dr. Wehberg will be presenting on a group of 25 consecutive patients
treated with the Cardiogenesis holmium: YAG Laser TMR System. Eleven
patients in the series received a combination therapy of TMR with an
intramyocardial injection of autologous PRP, which is a concentration of
platelets, white blood cells and circulating stem cells from the patients'
own peripheral blood. At six months, a blinded angina assessment
-- Both groups achieved significant angina relief.
-- The TMR + PRP group had a lower average angina score (0.4 vs 1.7,
p=0.07) than the TMR alone group, and were more likely to be angina
free (71% vs 23%, p=0.04).
-- Ejection fraction (EF) improved in the TMR + PRP group (+9.0% vs.
-2.0%, p=0.07) compared to the TMR group.
The authors conclude, "These preliminary results suggest that combining intramyocardial injection of PRP with TMR may be more efficacious at relieving angina and improving myocardial function than TMR alone."
Richard Lanigan, President of Cardiogenesis, noted, "The results that
Dr. Wehberg wil
|SOURCE Cardiogenesis Corporation|
Copyright©2008 PR Newswire.
All rights reserved